GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (NYSE:ABT) » Definitions » ROC (Joel Greenblatt) %

Abbott Laboratories (Abbott Laboratories) ROC (Joel Greenblatt) %

: 73.60% (As of Dec. 2023)
View and export this data going back to 1949. Start your Free Trial

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Abbott Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 73.60%.

The historical rank and industry rank for Abbott Laboratories's ROC (Joel Greenblatt) % or its related term are showing as below:

ABT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 29.84   Med: 55.53   Max: 97.83
Current: 72.21

During the past 13 years, Abbott Laboratories's highest ROC (Joel Greenblatt) % was 97.83%. The lowest was 29.84%. And the median was 55.53%.

ABT's ROC (Joel Greenblatt) % is ranked better than
94.12% of 851 companies
in the Medical Devices & Instruments industry
Industry Median: 0.75 vs ABT: 72.21

Abbott Laboratories's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 13.10% per year.


Abbott Laboratories ROC (Joel Greenblatt) % Historical Data

The historical data trend for Abbott Laboratories's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.86 63.30 97.22 97.83 74.16

Abbott Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.06 72.62 71.24 69.53 73.60

Competitive Comparison

For the Medical Devices subindustry, Abbott Laboratories's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbott Laboratories ROC (Joel Greenblatt) % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories's ROC (Joel Greenblatt) % falls into.



Abbott Laboratories ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6499 + 6650 + 0) - (11991 + 0 + 0)
=1158

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6565 + 6570 + 0) - (12761 + 0 + 0)
=374

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Abbott Laboratories for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=7816/( ( (9552 + max(1158, 0)) + (10154 + max(374, 0)) )/ 2 )
=7816/( ( 10710 + 10528 )/ 2 )
=7816/10619
=73.60 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbott Laboratories  (NYSE:ABT) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Abbott Laboratories ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbott Laboratories (Abbott Laboratories) Business Description

Address
100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Executives
Andrea F Wainer officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Mccoy John A. Jr. officer: VICE PRESIDENT C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael F Roman director 3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000
Patricia Paola Gonzalez director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Louis H. Morrone officer: EXECUTIVE VICE PRESIDENT 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip P Boudreau officer: Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael O'grady director 50 S LASALLE STREET, CHICAGO IL 60603
Gregory A Ahlberg officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Randel William Woodgrift officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
John F Ginascol officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Salvadori Daniel Gesua Sive officer: Senior Vice President 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092
Mary K Moreland officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Lisa D Earnhardt officer: Executive Vice President 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Robert E Funck officer: Vice President, Controller 100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092

Abbott Laboratories (Abbott Laboratories) Headlines

From GuruFocus

Q4 2022 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2018 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2019 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2020 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024